Tag: advocacy news
EHA welcomes European Parliament backing for SoHO legislation
EHA welcomes the European Parliament’s backing for SoHO legislation that puts patient safety and supply sustainability first.
Strengthening Resilience and Fostering Collaboration: Ensuring a Transparent and…
The issue of immunoglobulin shortages and the importance of enhancing and maintaining plasma supplies have gained significant attention within the policy and regulatory landscape of the European Union.
More than science: the European Affairs program at EHA2023
The ‘EU & Hematology track’ and other European Affairs activities at EHA2023 shed light on important regulatory developments and offer a platform for dialogue between hematologists, patients and other stakeholders.
Immunoglobulin shortages in the spotlight: EMA, SUPPLY and the SoHO Regulation
EMA executive director Emer Cooke welcoming participants including EHA at the Shortages Workshop, March 1 Shortages of immunoglobulins and the need to increase and sustain plasma supplies have moved to the…
EHA supports the proposal for a Regulation on the European Health Data Space (EH…
On October 20, the European Hematology Association (EHA) joined a group of 35 stakeholders in welcoming the European Commission’s proposal on the European Health Data Space.
EHA to the European Commission and HTA leaders: work with medical societies to i…
The speakers of the HTA conference hosted by the European Commission.
EU funding approved for TOLERATE
On April 1, the European Commission approved funding for the TOLERATE training network, proposed by a KU Leuven-led consortium including EHA.
EU pilot on drug repurposing
Drug repurposing (finding new indications for existing authorized medicines) is increasingly prominent in the debate about improving access to medicines.
EU Calls for Proposal 2022
Introduction Spurred by COVID-19 and rising challenges to the financial sustainability of Europe’s health systems, a flurry of new EU policies and programs in health has sprung up since last year.…
EU Calls for proposal 2021
Spurred by COVID-19 and rising challenges to the financial sustainability of Europe’s health systems, a flurry of new EU policies and programs in health has sprung up since last year. Some of the most eye-catching initiatives are highly relevant for hematology: the Europe’s Beating Cancer Plan, the Pharmaceutical Strategy and the European Health Data Space.
EHA has joined the European Cancer Organisation - a perfect match on objectives …
The European Hematology Association (EHA) has joined the European Cancer Organisation, a not-for-profit federation of organizations working in cancer at the European level. EHA’s membership application was approved by the General Assembly of the European Cancer Organisation on November 18, 2020.
Call for urgent action on medicine shortages in Europe
EPHA published a position paper on medicine shortages in Europe. EHA welcomes its recommendations to address the increasing shortages crisis, which threatens patient outcomes and patient safety.
ATMPs and CAR-T: the uptake challenge
Advanced therapy medicinal products (ATMPs) are a game changer for improving the lives of patients with severe to life-threatening diseases. Yet, despite fast-paced innovation in the field, few ATMPs have reached the EU market and benefited patients. The challenges facing their adoption by health systems are complex. A test case is the uptake of CAR T-cell therapy; what are the hurdles and what action is needed from stakeholders?
EU health policy: limited scope, high ambition
While health policy remains the primary responsibility of Member States, in many areas the added value of EU-level collaboration and harmonization has increased. EU initiatives in health have shown a mixed record in terms of impact, but hopes are high for the latest one, the ambitious Europe’s Beating Cancer Plan.
Revising the ICH Guidelines on Clinical Trials
Clinical trials and drug development have become more complex over the years. One complicating factor is the increased administrative burden, as was pointed out in the previous edition of HemAffairs. Doctors and clinical researchers are more and more bound to rules they deem neither necessary nor effective. At first sight, the requirements for clinical trials seem clear and thorough. Nonetheless, the interpretation and implementation of these rules leave room for improvement.